Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2007-12

AUTHORS

Ulrich Kintscher, Peter Bramlage, W Dieter Paar, Martin Thoenes, Thomas Unger

ABSTRACT

OBJECTIVES: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARgamma) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care. RESEARCH DESIGN AND METHODS: Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed. MAIN OUTCOME MEASURES: Systolic (SBP) and diastolic (DBP) blood pressure reduction, response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs). RESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE. CONCLUSION: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile. More... »

PAGES

12

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1475-2840-6-12

DOI

http://dx.doi.org/10.1186/1475-2840-6-12

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040398603

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17407587


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Abdominal Fat", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II Type 1 Receptor Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biphenyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, HDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fasting", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydrochlorothiazide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolic Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triglycerides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Charit\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charit\u00e9, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kintscher", 
        "givenName": "Ulrich", 
        "id": "sg:person.0636477725.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636477725.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "TU Dresden", 
          "id": "https://www.grid.ac/institutes/grid.4488.0", 
          "name": [
            "Institute for Clinical Pharmacology, Medical Faculty Carl-Gustav Carus, Technical University Dresden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bramlage", 
        "givenName": "Peter", 
        "id": "sg:person.01304431360.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304431360.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420214.1", 
          "name": [
            "Sanofi-Aventis Deutschland GmbH, Medical Affairs CardioVascularThrombosis, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paar", 
        "givenName": "W Dieter", 
        "id": "sg:person.01220266165.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220266165.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (France)", 
          "id": "https://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi-Aventis, Medical Affairs, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thoenes", 
        "givenName": "Martin", 
        "id": "sg:person.01205715672.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205715672.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Charit\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charit\u00e9, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Unger", 
        "givenName": "Thomas", 
        "id": "sg:person.0752125516.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752125516.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001250051268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001153018", 
          "https://doi.org/10.1007/s001250051268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250051268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001153018", 
          "https://doi.org/10.1007/s001250051268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-200406000-00024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002454474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-200406000-00024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002454474"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199917020-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003918995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199917020-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003918995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199917020-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003918995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-200020010-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004560003", 
          "https://doi.org/10.2165/00044011-200020010-00001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-200020010-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004560003", 
          "https://doi.org/10.2165/00044011-200020010-00001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000123072.34629.57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005277791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000123072.34629.57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005277791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.24.4.683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005367642"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000168046.19884.6a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007193277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000168046.19884.6a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007193277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000168046.19884.6a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007193277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1524-6175.2004.04720.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008782891"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.26.3.575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009237000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.288.21.2709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009474275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000080897.52664.94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010001455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199200441-00013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010937770", 
          "https://doi.org/10.2165/00003495-199200441-00013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1262-3636(07)70067-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014292627"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.288.23.2981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016077891"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3317/jraas.2003.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018201506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3317/jraas.2003.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018201506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2840-4-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018238203", 
          "https://doi.org/10.1186/1475-2840-4-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00038-004-3063-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022661411", 
          "https://doi.org/10.1007/s00038-004-3063-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000127955.36250.65", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029448060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000133732.24501.9e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030294418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000133732.24501.9e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030294418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.105.169404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030755840"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000141736.76561.78", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032387441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.nutr.23.011702.073212", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033009996"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000215181.60228.f7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038043341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000215181.60228.f7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038043341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.nutr.22.010402.102808", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038789731"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1373/clinchem.2006.067397", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038911332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079904x3861", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040600148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.93.22.12490", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041835884"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/hy1101.092970", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042478946"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)08089-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044050224"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-199918060-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047815854", 
          "https://doi.org/10.2165/00044011-199918060-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000242405.68461.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051813961"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.hjh.0000242405.68461.84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051813961"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1440-1681.2003.03911.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052144102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200006223422507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053038763"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.febslet.2004.09.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054735137"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem.87.2.7980", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064324894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circ.106.25.3143", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075204771"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077945134", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-12", 
    "datePublishedReg": "2007-12-01", 
    "description": "OBJECTIVES: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARgamma) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care.\nRESEARCH DESIGN AND METHODS: Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed.\nMAIN OUTCOME MEASURES: Systolic (SBP) and diastolic (DBP) blood pressure reduction, response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs).\nRESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE.\nCONCLUSION: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1475-2840-6-12", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031021", 
        "issn": [
          "1475-2840"
        ], 
        "name": "Cardiovascular Diabetology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "name": "Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients", 
    "pagination": "12", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c070b3291c4375024196f75880e81cee1b40e443baeb119fe36879fbf8ec1a8d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17407587"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101147637"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1475-2840-6-12"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040398603"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1475-2840-6-12", 
      "https://app.dimensions.ai/details/publication/pub.1040398603"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1475-2840-6-12"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1475-2840-6-12'


 

This table displays all metadata directly associated to this object as RDF triples.

313 TRIPLES      21 PREDICATES      89 URIs      44 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1475-2840-6-12 schema:about N058e4e5c9a644012a0dedd2ce8a1a4e0
2 N0e192183d1514f1b8c44d04733dfd6bb
3 N10a357a124b845058e0c2699bb20080e
4 N1553b8a66f6a4c60949766c1ecc1e85a
5 N27a6a15ca2dd4353ba053c1be810d067
6 N2ca351140d84430489a8c742d14e60ca
7 N4877f7d1e8b747b9bb41a325891682fd
8 N51ee3cd2091e4cd38d6f0fc87a5e2847
9 N68b09e9b4bca4b538d9643cff7ca4a41
10 N73357e763baf4f46a51837d393858826
11 N8ee38ad484564c648c7da86f5d124fbd
12 N965419c24e4b4e06a5e5d2ebe884f61a
13 N9da88adf0b1f4703898fcdc2597774b1
14 Na755bd308d444e6c81c055557e5298c5
15 Nb00933256038437ea5d0ea46a4afa6e9
16 Ncaa9b949e42b4aa98debbb7e57b29219
17 Ncac22cd8b91f4c33a37ec17312364052
18 Nd0dc21059d1446d28d5b3a36cfac6eec
19 Nd47b36bd641d4a4284f4b55b9f4cd36e
20 Ndef56df378004213bfd59f8c9bb6eaae
21 Nee0e4d1d96cc47f3baf54fd93e4e337b
22 Nf148ca2620554c899281935dda5752af
23 Nff81145c3c514b98a95ce143fe125f45
24 anzsrc-for:11
25 anzsrc-for:1102
26 schema:author N2777f9846678400a8f8ac195a80b8eae
27 schema:citation sg:pub.10.1007/s00038-004-3063-5
28 sg:pub.10.1007/s001250051268
29 sg:pub.10.1186/1475-2840-4-6
30 sg:pub.10.2165/00003495-199200441-00013
31 sg:pub.10.2165/00044011-199918060-00004
32 sg:pub.10.2165/00044011-200020010-00001
33 https://app.dimensions.ai/details/publication/pub.1077945134
34 https://doi.org/10.1001/jama.288.21.2709
35 https://doi.org/10.1001/jama.288.23.2981
36 https://doi.org/10.1016/j.febslet.2004.09.027
37 https://doi.org/10.1016/s0140-6736(02)08089-3
38 https://doi.org/10.1016/s1262-3636(07)70067-8
39 https://doi.org/10.1046/j.1440-1681.2003.03911.x
40 https://doi.org/10.1056/nejm200006223422507
41 https://doi.org/10.1073/pnas.93.22.12490
42 https://doi.org/10.1097/00004872-199917020-00001
43 https://doi.org/10.1097/00004872-200406000-00024
44 https://doi.org/10.1097/01.hjh.0000133732.24501.9e
45 https://doi.org/10.1097/01.hjh.0000242405.68461.84
46 https://doi.org/10.1111/j.1524-6175.2004.04720.x
47 https://doi.org/10.1146/annurev.nutr.22.010402.102808
48 https://doi.org/10.1146/annurev.nutr.23.011702.073212
49 https://doi.org/10.1161/01.cir.0000080897.52664.94
50 https://doi.org/10.1161/01.cir.0000127955.36250.65
51 https://doi.org/10.1161/01.cir.0000141736.76561.78
52 https://doi.org/10.1161/01.hyp.0000123072.34629.57
53 https://doi.org/10.1161/01.hyp.0000168046.19884.6a
54 https://doi.org/10.1161/01.hyp.0000215181.60228.f7
55 https://doi.org/10.1161/circ.106.25.3143
56 https://doi.org/10.1161/circulationaha.105.169404
57 https://doi.org/10.1161/hy1101.092970
58 https://doi.org/10.1185/030079904x3861
59 https://doi.org/10.1210/jcem.87.2.7980
60 https://doi.org/10.1373/clinchem.2006.067397
61 https://doi.org/10.2337/diacare.24.4.683
62 https://doi.org/10.2337/diacare.26.3.575
63 https://doi.org/10.3317/jraas.2003.026
64 schema:datePublished 2007-12
65 schema:datePublishedReg 2007-12-01
66 schema:description OBJECTIVES: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARgamma) activating properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care. RESEARCH DESIGN AND METHODS: Multicenter, prospective, two-armed, post authorization study over 9 months in 14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular risk factors making up the criteria for the metabolic syndrome were assessed. MAIN OUTCOME MEASURES: Systolic (SBP) and diastolic (DBP) blood pressure reduction, response, and normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome. Number and nature of adverse events (AEs). RESULTS: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -26.3 +/- 10.1 mmHg/DBP-13.0 +/- 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 +/- 7.2 mg/dl in men, +3.8 +/- 6.5 mg/dl in women, both p < 0.0001), serum triglycerides (-28.6 +/- 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 +/- 25.1 mg/dl, p < 0.0001) and waist circumference (-2.4 +/- 11.9 cm in men, -1.2 +/- 14.2 in women, both p < 0.0001) were significantly improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure reduction (SBP: -27.5 +/- 10.1 mmHg/DBP: -14.1 +/- 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0 +/- 6.8 mg/dl in men, +3.4 +/- 6.8 in women, both p < 0.0001), triglycerides (-34.1 +/- 52.6 mg/dl, p < 0.0001), fasting blood glucose (-10.0 +/- 24.7, p < 0.0001) and waist circumference (-3.2 +/- 12.7 cm in men, -1.7 +/- 14.4 in women, both p < 0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE. CONCLUSION: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the cardiovascular risk profile.
67 schema:genre research_article
68 schema:inLanguage en
69 schema:isAccessibleForFree true
70 schema:isPartOf Nabb91be5a1e1436bb615219b85513b62
71 Nd1860abbe1224863a409a9e129be8c16
72 sg:journal.1031021
73 schema:name Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients
74 schema:pagination 12
75 schema:productId N3a8f1e479e6f41beafae4574eb2fcf6c
76 N563b3bca1caa4cd0ae2b2b04ca956cac
77 N71f8f107f009433c9a8f634a05cf2b10
78 N887374df1a9b4dacb80b7869fb64897e
79 Nd7375c46529047f7851237e7d686bcd1
80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040398603
81 https://doi.org/10.1186/1475-2840-6-12
82 schema:sdDatePublished 2019-04-10T20:47
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher N83e0d439f3204977bc09aaf814c94243
85 schema:url http://link.springer.com/10.1186%2F1475-2840-6-12
86 sgo:license sg:explorer/license/
87 sgo:sdDataset articles
88 rdf:type schema:ScholarlyArticle
89 N058e4e5c9a644012a0dedd2ce8a1a4e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Hypertension
91 rdf:type schema:DefinedTerm
92 N0e192183d1514f1b8c44d04733dfd6bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Aged
94 rdf:type schema:DefinedTerm
95 N10a357a124b845058e0c2699bb20080e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Tetrazoles
97 rdf:type schema:DefinedTerm
98 N1553b8a66f6a4c60949766c1ecc1e85a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Drug Therapy, Combination
100 rdf:type schema:DefinedTerm
101 N2777f9846678400a8f8ac195a80b8eae rdf:first sg:person.0636477725.27
102 rdf:rest N4794eaf375074c688c13fc6567b00aea
103 N27a6a15ca2dd4353ba053c1be810d067 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Female
105 rdf:type schema:DefinedTerm
106 N2ca351140d84430489a8c742d14e60ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Humans
108 rdf:type schema:DefinedTerm
109 N3a8f1e479e6f41beafae4574eb2fcf6c schema:name readcube_id
110 schema:value c070b3291c4375024196f75880e81cee1b40e443baeb119fe36879fbf8ec1a8d
111 rdf:type schema:PropertyValue
112 N4794eaf375074c688c13fc6567b00aea rdf:first sg:person.01304431360.27
113 rdf:rest Ned7bef2fc6f049a0bf6a4b476977a007
114 N4877f7d1e8b747b9bb41a325891682fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Biphenyl Compounds
116 rdf:type schema:DefinedTerm
117 N51ee3cd2091e4cd38d6f0fc87a5e2847 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Metabolic Syndrome
119 rdf:type schema:DefinedTerm
120 N563b3bca1caa4cd0ae2b2b04ca956cac schema:name dimensions_id
121 schema:value pub.1040398603
122 rdf:type schema:PropertyValue
123 N581d7f0f5a5f47dba5ec4783c24dd0af rdf:first sg:person.01205715672.60
124 rdf:rest Ne57a145b6e424d8082f610c8f20aed72
125 N68b09e9b4bca4b538d9643cff7ca4a41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Hydrochlorothiazide
127 rdf:type schema:DefinedTerm
128 N71f8f107f009433c9a8f634a05cf2b10 schema:name nlm_unique_id
129 schema:value 101147637
130 rdf:type schema:PropertyValue
131 N73357e763baf4f46a51837d393858826 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Prospective Studies
133 rdf:type schema:DefinedTerm
134 N83e0d439f3204977bc09aaf814c94243 schema:name Springer Nature - SN SciGraph project
135 rdf:type schema:Organization
136 N887374df1a9b4dacb80b7869fb64897e schema:name pubmed_id
137 schema:value 17407587
138 rdf:type schema:PropertyValue
139 N8ee38ad484564c648c7da86f5d124fbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Triglycerides
141 rdf:type schema:DefinedTerm
142 N965419c24e4b4e06a5e5d2ebe884f61a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Blood Glucose
144 rdf:type schema:DefinedTerm
145 N9da88adf0b1f4703898fcdc2597774b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Fasting
147 rdf:type schema:DefinedTerm
148 Na755bd308d444e6c81c055557e5298c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Blood Pressure
150 rdf:type schema:DefinedTerm
151 Nabb91be5a1e1436bb615219b85513b62 schema:volumeNumber 6
152 rdf:type schema:PublicationVolume
153 Nb00933256038437ea5d0ea46a4afa6e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Middle Aged
155 rdf:type schema:DefinedTerm
156 Ncaa9b949e42b4aa98debbb7e57b29219 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Abdominal Fat
158 rdf:type schema:DefinedTerm
159 Ncac22cd8b91f4c33a37ec17312364052 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Cohort Studies
161 rdf:type schema:DefinedTerm
162 Nd0dc21059d1446d28d5b3a36cfac6eec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Cholesterol, HDL
164 rdf:type schema:DefinedTerm
165 Nd1860abbe1224863a409a9e129be8c16 schema:issueNumber 1
166 rdf:type schema:PublicationIssue
167 Nd47b36bd641d4a4284f4b55b9f4cd36e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Male
169 rdf:type schema:DefinedTerm
170 Nd7375c46529047f7851237e7d686bcd1 schema:name doi
171 schema:value 10.1186/1475-2840-6-12
172 rdf:type schema:PropertyValue
173 Ndef56df378004213bfd59f8c9bb6eaae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Cardiovascular Diseases
175 rdf:type schema:DefinedTerm
176 Ne57a145b6e424d8082f610c8f20aed72 rdf:first sg:person.0752125516.35
177 rdf:rest rdf:nil
178 Ned7bef2fc6f049a0bf6a4b476977a007 rdf:first sg:person.01220266165.99
179 rdf:rest N581d7f0f5a5f47dba5ec4783c24dd0af
180 Nee0e4d1d96cc47f3baf54fd93e4e337b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Risk Factors
182 rdf:type schema:DefinedTerm
183 Nf148ca2620554c899281935dda5752af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Angiotensin II Type 1 Receptor Blockers
185 rdf:type schema:DefinedTerm
186 Nff81145c3c514b98a95ce143fe125f45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Antihypertensive Agents
188 rdf:type schema:DefinedTerm
189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
190 schema:name Medical and Health Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
193 schema:name Cardiorespiratory Medicine and Haematology
194 rdf:type schema:DefinedTerm
195 sg:journal.1031021 schema:issn 1475-2840
196 schema:name Cardiovascular Diabetology
197 rdf:type schema:Periodical
198 sg:person.01205715672.60 schema:affiliation https://www.grid.ac/institutes/grid.417924.d
199 schema:familyName Thoenes
200 schema:givenName Martin
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205715672.60
202 rdf:type schema:Person
203 sg:person.01220266165.99 schema:affiliation https://www.grid.ac/institutes/grid.420214.1
204 schema:familyName Paar
205 schema:givenName W Dieter
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220266165.99
207 rdf:type schema:Person
208 sg:person.01304431360.27 schema:affiliation https://www.grid.ac/institutes/grid.4488.0
209 schema:familyName Bramlage
210 schema:givenName Peter
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304431360.27
212 rdf:type schema:Person
213 sg:person.0636477725.27 schema:affiliation https://www.grid.ac/institutes/grid.6363.0
214 schema:familyName Kintscher
215 schema:givenName Ulrich
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636477725.27
217 rdf:type schema:Person
218 sg:person.0752125516.35 schema:affiliation https://www.grid.ac/institutes/grid.6363.0
219 schema:familyName Unger
220 schema:givenName Thomas
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752125516.35
222 rdf:type schema:Person
223 sg:pub.10.1007/s00038-004-3063-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022661411
224 https://doi.org/10.1007/s00038-004-3063-5
225 rdf:type schema:CreativeWork
226 sg:pub.10.1007/s001250051268 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001153018
227 https://doi.org/10.1007/s001250051268
228 rdf:type schema:CreativeWork
229 sg:pub.10.1186/1475-2840-4-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018238203
230 https://doi.org/10.1186/1475-2840-4-6
231 rdf:type schema:CreativeWork
232 sg:pub.10.2165/00003495-199200441-00013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010937770
233 https://doi.org/10.2165/00003495-199200441-00013
234 rdf:type schema:CreativeWork
235 sg:pub.10.2165/00044011-199918060-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047815854
236 https://doi.org/10.2165/00044011-199918060-00004
237 rdf:type schema:CreativeWork
238 sg:pub.10.2165/00044011-200020010-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004560003
239 https://doi.org/10.2165/00044011-200020010-00001
240 rdf:type schema:CreativeWork
241 https://app.dimensions.ai/details/publication/pub.1077945134 schema:CreativeWork
242 https://doi.org/10.1001/jama.288.21.2709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009474275
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1001/jama.288.23.2981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016077891
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1016/j.febslet.2004.09.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054735137
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1016/s0140-6736(02)08089-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044050224
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/s1262-3636(07)70067-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014292627
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1046/j.1440-1681.2003.03911.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052144102
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1056/nejm200006223422507 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053038763
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1073/pnas.93.22.12490 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041835884
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1097/00004872-199917020-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003918995
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1097/00004872-200406000-00024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002454474
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1097/01.hjh.0000133732.24501.9e schema:sameAs https://app.dimensions.ai/details/publication/pub.1030294418
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1097/01.hjh.0000242405.68461.84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051813961
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1111/j.1524-6175.2004.04720.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008782891
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1146/annurev.nutr.22.010402.102808 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038789731
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1146/annurev.nutr.23.011702.073212 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033009996
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1161/01.cir.0000080897.52664.94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010001455
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1161/01.cir.0000127955.36250.65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029448060
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1161/01.cir.0000141736.76561.78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032387441
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1161/01.hyp.0000123072.34629.57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005277791
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1161/01.hyp.0000168046.19884.6a schema:sameAs https://app.dimensions.ai/details/publication/pub.1007193277
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1161/01.hyp.0000215181.60228.f7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038043341
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1161/circ.106.25.3143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075204771
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1161/circulationaha.105.169404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030755840
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1161/hy1101.092970 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042478946
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1185/030079904x3861 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040600148
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1210/jcem.87.2.7980 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064324894
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1373/clinchem.2006.067397 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038911332
295 rdf:type schema:CreativeWork
296 https://doi.org/10.2337/diacare.24.4.683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005367642
297 rdf:type schema:CreativeWork
298 https://doi.org/10.2337/diacare.26.3.575 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009237000
299 rdf:type schema:CreativeWork
300 https://doi.org/10.3317/jraas.2003.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018201506
301 rdf:type schema:CreativeWork
302 https://www.grid.ac/institutes/grid.417924.d schema:alternateName Sanofi (France)
303 schema:name Sanofi-Aventis, Medical Affairs, Paris, France
304 rdf:type schema:Organization
305 https://www.grid.ac/institutes/grid.420214.1 schema:alternateName Sanofi (Germany)
306 schema:name Sanofi-Aventis Deutschland GmbH, Medical Affairs CardioVascularThrombosis, Berlin, Germany
307 rdf:type schema:Organization
308 https://www.grid.ac/institutes/grid.4488.0 schema:alternateName TU Dresden
309 schema:name Institute for Clinical Pharmacology, Medical Faculty Carl-Gustav Carus, Technical University Dresden, Germany
310 rdf:type schema:Organization
311 https://www.grid.ac/institutes/grid.6363.0 schema:alternateName Charité
312 schema:name Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité, Berlin, Germany
313 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...